Prostate Cancer最新文献

{"title":"Complications of Extended Pelvic Lymph Node Dissection in Patients Undergoing Minimally Invasive Radical Prostatectomy: Analysis and Risk Factors.","authors":"Pedro Castro,&nbsp;Paulo B O Arantes,&nbsp;Yves M R Martins,&nbsp;Matheus N M Reis,&nbsp;Ana Paula Drummond-Lage,&nbsp;Alberto J A Wainstein","doi":"10.1155/2022/7631903","DOIUrl":"https://doi.org/10.1155/2022/7631903","url":null,"abstract":"<p><strong>Background: </strong>The knowledge of risk factors and complications related to extended pelvic lymph node dissection (ePLND) during radical prostatectomy can help selecting patients who will benefit the most with lymph node dissection concomitant to radical prostatectomy.</p><p><strong>Materials and methods: </strong>Retrospective cohort evaluating 135 patients with PC, with a high risk for lymph node metastasis, submitted to ePLND by a single surgeon between 2013 and 2019, performed either by the laparoscopic or laparoscopic robot-assisted approach. Data related to complications were properly recorded using the Martin's criteria and were classified by the Satava and Clavien-Dindo-Strasberg methods. Logistic regression was used to determine predictors of complications related to ePLND.</p><p><strong>Results: </strong>The mean number of lymph nodes removed was 10.2 ± 4.9, and in 28.2%, they were positive for metastasis. There were five intraoperative complications (4%), all in patients operated by laparoscopic approach. There were nine severe postoperative complications (7.3%), four of which occurred after postoperative day 30. Three patients (2.4%) had thromboembolic complications and five patients (4.0%) had lymphocele that required treatment. There was a correlation between the American Society of Anesthesiologists (ASA) physical status classification and postoperative complications (<i>p</i>=0.06), but it was not possible to identify statistically significant predictors.</p><p><strong>Conclusion: </strong>ePLND during radical prostatectomy has a low rate of intraoperative complications and may change prostate cancer staging. Postoperative complications, especially venous thromboembolism and lymphocele, need to be monitored even in the late postoperative period.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":" ","pages":"7631903"},"PeriodicalIF":4.2,"publicationDate":"2022-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40674364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue.","authors":"Linh T Nguyen,&nbsp;Charlotte S Lo,&nbsp;Michael Fyrsta,&nbsp;Jessica Nie,&nbsp;Jennifer Y Yam,&nbsp;Pei-Hua Yen,&nbsp;Michael X Le,&nbsp;Karen Hersey,&nbsp;Miran Kenk,&nbsp;Megan Crumbaker,&nbsp;Neil Fleshner,&nbsp;Girish Kulkarni,&nbsp;Robert Hamilton,&nbsp;Michael Jewett,&nbsp;Antonio Finelli,&nbsp;Andrew Evans,&nbsp;Joan Sweet,&nbsp;Pamela S Ohashi,&nbsp;Anthony M Joshua","doi":"10.1155/2022/6499344","DOIUrl":"https://doi.org/10.1155/2022/6499344","url":null,"abstract":"<p><strong>Background: </strong>The evaluation of tumour-infiltrating lymphocytes (TILs) in solid malignancies has yielded insights into immune regulation within the tumour microenvironment and has also led to the development and optimisation of adoptive T cell therapies.</p><p><strong>Objectives: </strong>This study examined the <i>in vitro</i> expansion of TILs from prostate adenocarcinoma, as a preliminary step to evaluate the potential of TILs for adoptive T cell therapy. <i>Design, Setting, and Participants</i>. Malignant and adjacent nonmalignant tissues were obtained from fifteen men undergoing radical prostatectomy. <i>Interventions</i>. There were no study interventions. <i>Outcome Measurements and Statistical Analysis</i>. Expanded cells were analysed by flow cytometry, and the data was assessed for associations between cell subpopulations and expansion rate.</p><p><strong>Results: </strong>Tumour-infiltrating lymphocytes could be expanded to numbers that would be needed to generate a therapeutic infusion product from nine of 15 malignant specimens (60%). The CD4⁺ T cells predominated over CD8⁺ T cells (median 56.8% CD4⁺, 30.0% CD8⁺), and furthermore, faster TIL expansion was associated with a higher proportion of CD4⁺ T cells (median 69.8% in faster-growing cultures; 36.8% in slower-growing cultures). A higher proportion of CD3^-CD56⁺ cells versus CD3⁺ cells was associated with slower TIL expansion in cultures from malignant specimens (median 13.3% in slower-growing cultures versus 2.05% in faster-growing cultures), but not from nonmalignant specimens.</p><p><strong>Conclusions: </strong>The expansion of TILs for potential therapeutic use is feasible. Our findings also indicate that further examination of TILs from prostate adenocarcinomas may yield insights into mechanisms of regulation of T cells within the tumour microenvironment. Further research is required to evaluate their therapeutic potential.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":" ","pages":"6499344"},"PeriodicalIF":4.2,"publicationDate":"2022-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40398433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRI-Based Radiotherapy Planning to Reduce Rectal Dose in Excess of Tolerance.","authors":"Daniel R Schmidt,&nbsp;Mandar Bhagwat,&nbsp;Daniel I Glazer,&nbsp;Ming-Hui Chen,&nbsp;Maryam Moteabbed,&nbsp;Elizabeth McMahon,&nbsp;Marian J Loffredo,&nbsp;Clare M Tempany,&nbsp;Anthony V D'Amico","doi":"10.1155/2022/7930744","DOIUrl":"https://doi.org/10.1155/2022/7930744","url":null,"abstract":"<p><strong>Materials and methods: </strong>This prospective single-arm study enrolled 15 men treated with IG-IMRT for localized prostate cancer. All participants received a dedicated 3 Tesla MRI examination of the prostate in addition to a pelvic CT examination for treatment planning. Two volumetric modulated arc therapy (VMAT) plans with a prescription dose of 79.2 Gy were designed using identical constraints based on CT- and MRI-defined consensus volumes. The volume of rectum exposed to 70 Gy or more was compared using the Wilcoxon paired signed rank test.</p><p><strong>Results: </strong>For CT-based treatment plans, the median volume of rectum receiving 70 Gy or more was 9.3 cubic centimeters (cc) (IQR 7.0 to 10.2) compared with 4.9 cc (IQR 4.1 to 7.8) for MRI-based plans. This resulted in a median volume reduction of 2.1 cc (IQR 0.5 to 5.3, <i>P</i> < .001).</p><p><strong>Conclusions: </strong>Using MRI to plan prostate IG-IMRT to a dose of 79.2 Gy reduces the volume of rectum receiving radiation dose in excess of tolerance (70 Gy or more) and should be considered in men who are at high risk for late rectal toxicity and are not good candidates for other rectal sparing techniques such as hydrogel spacer. This trial is registered with NCT02470910.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":" ","pages":"7930744"},"PeriodicalIF":4.2,"publicationDate":"2022-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39914899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate-Specific Antigen Screening According to Health Professional Counseling and Age in the United States.","authors":"Ray M Merrill,&nbsp;Seth A Otto,&nbsp;Eliza B Hammond","doi":"10.1155/2022/8646314","DOIUrl":"https://doi.org/10.1155/2022/8646314","url":null,"abstract":"<p><strong>Background: </strong>In 2018, the US Preventive Services Task Force recommended that PSA screening for prostate cancer involve men aged 55-69, based on a personal decision following consultation with a health professional. PSA screening in men aged 70 or older should only occur if symptoms exist. This study identifies the association between having a PSA test in the past two years and whether or not there was consultation with a health professional about the benefits and/or harms of PSA screening.</p><p><strong>Methods: </strong>Analyses were based on data involving men aged 40 years or older, who responded to PSA related questions in the 2018 BRFSS survey.</p><p><strong>Results: </strong>Approximately 32.0% (14.6% for ages 40-54, 41.7% for ages 55-69, and 49.8% for ages 70 years and older) of respondents had a PSA test in the past two years. Approximately 81.7% of these men had talked with a health professional about the benefits and/or harms of PSA screening, with 42.4% having discussed the benefits and harms, 54.6% having discussed the benefits only, and 3.0% having discussed the harms only. The odds of a PSA test in the past two years in men having talked with a health professional about the benefits and harms of the test versus no talk are 10.1 (95% CI 9.3-10.8), in men who talked with a health professional about the benefits only versus no talk are 10.8 (95% CI 10.0-11.6), and in men who talked with a health professional about the harms only versus no talk are 3.9 (95% CI 2.9-5.1).</p><p><strong>Conclusion: </strong>PSA screening is most common in men aged 70 or older, which is counter to the US Preventive Task Force recommendation. Most men having a PSA test have talked with a health professional about the test, but the talks tended to focus on just the benefits of screening and not both potential benefits and harms.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":" ","pages":"8646314"},"PeriodicalIF":4.2,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39825670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review.","authors":"Seyyedmohammadsadeq Mirmoeeni,&nbsp;Amirhossein Azari Jafari,&nbsp;Muffaqam Shah,&nbsp;Fateme Salemi,&nbsp;Seyedeh Zohreh Hashemi,&nbsp;Ali Seifi","doi":"10.1155/2022/5324600","DOIUrl":"https://doi.org/10.1155/2022/5324600","url":null,"abstract":"<p><strong>Aim: </strong>Prostate cancer (PCa) is the second most common nonskin malignancy and the second most common cause of cancer-related deaths in men. The most common site of metastasis in PCa is the axial skeleton which may lead to back pain or pathological fractures. Hematogenous spread to the brain and involvement of the central nervous system (CNS) are a rare occurrence. However, failed androgen deprivation therapy (ADT) may facilitate such a spread resulting in an advanced metastatic stage of PCa, which carries a poor prognosis.</p><p><strong>Methods: </strong>In this systematic review, we searched the PubMed, Scopus, and Web of Science online databases based on the PRISMA guideline and used all the medical subject headings (MeSH) in terms of the following search line: (\"Brain Neoplasms\" OR \"Central Nervous System Neoplasms\") and (\"Prostatic Neoplasms\" OR \"Prostate\"). Related studies were identified and reviewed.</p><p><strong>Results: </strong>A total of 59 eligible studies (902 patients) were included in this systematic review. In order to gain a deeper understanding, we extracted and presented the data from included articles based on clinical manifestations, diagnostic methods, therapeutic approaches, and prognostic status of PCa patients having BMs.</p><p><strong>Conclusion: </strong>We have demonstrated the current knowledge regarding the mechanism, clinical manifestations, diagnostic methods, therapeutic approaches, and prognosis of BMs in PCa. These data shed more light on the way to help clinicians and physicians to understand, diagnose, and manage BMs in PCa patients better.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2022 ","pages":"5324600"},"PeriodicalIF":4.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso.","authors":"Aïda Djé Djénèba Traoré,&nbsp;Bienvenu Désiré Ky,&nbsp;Lassina Traoré,&nbsp;Théodora M Zohoncon,&nbsp;Abdou Azaque Zouré,&nbsp;Albert Théophane Yonli,&nbsp;Herman Karim Sombié,&nbsp;Pegdwendé Abel Sorgho,&nbsp;Bapio Valery Jean Télesphore Elvira Bazié,&nbsp;Sessi Frida Appoline Tovo,&nbsp;Essonan Kadanga,&nbsp;Bélélé Siméon Bakyono,&nbsp;Kalifou Traore,&nbsp;Teega-Wendé Clarisse Ouédraogo,&nbsp;Florencia W Djigma,&nbsp;Jacques Simpore","doi":"10.1155/2022/3610089","DOIUrl":"https://doi.org/10.1155/2022/3610089","url":null,"abstract":"<p><strong>Background: </strong>Genetic factors are one of the significant contributors to prostate cancer (PCa) development, and hereditary prostate cancer 2 (HPC2) locus gene ELAC2 is considered a PCa susceptibility region. The HPC2/ELAC2 gene has been identified by linkage analysis in familial prostate cancer patients in the United States but has never been studied in Burkina Faso. The objective of the present study was to analyze the carriage of the C650T (Ser217Leu) and G1621A (Ala541Thr) mutations of the ELAC2 gene and the risk factors in prostate cancer patients in Burkina Faso.</p><p><strong>Methods: </strong>This case-control study included 76 participants, including 38 histologically confirmed prostate cancer cases and 38 healthy controls without prostate abnormalities. PCR combined with restriction fragment length polymorphism (RFLP) was used to characterize the genotypes of the Ser217Leu and Ala541Thr polymorphisms of the ELAC2 gene. The correlations between the different genotypes and risk factors for prostate cancer were investigated.</p><p><strong>Results: </strong>The C650T mutation was present in 44.73% of prostate cancer cases and 47.37% of controls. The G1621A mutation was present in 26.32% of prostate cancer cases and 15.79% of controls. We did not detect an association between prostate cancer risk and the Ser217Leu (<i>p</i>=0.972) and Ala541Thr (<i>p</i>=0.267) variants of the ELAC2 gene. Also, the two ELAC2 SNPs did not correlate with clinical stage, prostate-specific antigen (PSA) level at diagnosis, or the Gleason score on biopsies. However, we found that 100% of homozygous carriers of the T650 mutation have an A1621 mutation (<i>p</i> ≤ 0.001).</p><p><strong>Conclusion: </strong>Ser217Leu and Ala541Thr polymorphisms of ELAC2, considered alone or in combination, are not associated with prostate cancer risk.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2022 ","pages":"3610089"},"PeriodicalIF":4.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10533994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.","authors":"Rahul Aggarwal,&nbsp;Joshi J Alumkal,&nbsp;Russell Z Szmulewitz,&nbsp;Celestia S Higano,&nbsp;Alan H Bryce,&nbsp;Angela Lopez-Gitlitz,&nbsp;Sharon A McCarthy,&nbsp;Branko Miladinovic,&nbsp;Kelly McQuarrie,&nbsp;Shibu Thomas,&nbsp;Ke Zhang,&nbsp;Eric J Small","doi":"10.1155/2022/5454727","DOIUrl":"https://doi.org/10.1155/2022/5454727","url":null,"abstract":"<p><strong>Purpose: </strong>This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BCR PC)<i>. Materials and Methods</i>. Patients with BCR PC after primary definitive therapy and prostate-specific antigen (PSA) doubling time ≤12 months were randomized to open-label apalutamide (240 mg/d) alone, apalutamide plus ADT, or ADT alone (1 : 1:1 ratio) for 12 months followed by a 12-month observation period (NCT01790126). Mean changes from baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) at 12 months (primary endpoint) and other prespecified assessments of health-related quality of life (HRQoL), PSA nadir, time to PSA progression, time to testosterone recovery, recovered testosterone >150 ng/dL without PSA progression at 24 months, and molecular markers were evaluated.</p><p><strong>Results: </strong>In 90 enrolled patients (apalutamide plus ADT (<i>n</i> = 31), apalutamide (<i>n</i> = 29), ADT (<i>n</i> = 30)), FACT-P at 12 months was not significantly different between apalutamide, ADT and apalutamide, and ADT groups. Addition of apalutamide to ADT prolonged time to PSA progression but this change did not reach statistical significance (hazard ratio (HR): 0.56, 95% confidence interval (CI): 0.23-1.36, <i>P</i>=0.196); time to testosterone recovery was similar in the ADT-containing groups. In apalutamide plus ADT, apalutamide, and ADT groups, 37.9%, 37.0%, and 19.2% of patients, respectively, had testosterone >150 ng/dL at 24 months without confirmed PSA progression. Of the few biomarkers expressed in blood, <i>EPHA3</i> was significantly associated with shorter time to PSA progression (<i>P</i>=0.02) in the overall population.</p><p><strong>Conclusions: </strong>HRQoL was similar in patients treated with apalutamide alone, ADT alone, or their combination, although apalutamide plus ADT did not demonstrate statistically significant noninferiority in change from baseline in overall HRQoL. The aggregated efficacy and safety outcomes support further evaluation of apalutamide plus ADT in BCR PC.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2022 ","pages":"5454727"},"PeriodicalIF":4.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9262848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cosmetic Appeal, HRQoL, and Effectiveness of Simple and Pseudotesticular Techniques of Orchidectomy in Prostate Cancer.","authors":"Ijeoma N C Chibuzo, Augustine O Takure, Olayiwola B Shittu, Linus I Okeke","doi":"10.1155/2021/9968570","DOIUrl":"10.1155/2021/9968570","url":null,"abstract":"<p><strong>Introduction: </strong>Orchidectomy is the most cost-effective means of hormonal therapy for locally advanced or metastatic prostate cancer (LAMP). However, cost-effectiveness should not detract from health-related quality of life (HRQoL) considerations. Bilateral simple orchidectomy (BSO) has been linked to negative psychometric deficits from an empty scrotum. This study compared the HRQoL, therapeutic efficacy, and cosmetic appeal of BSO with endogenous pseudotesticular techniques of bilateral subcapsular orchidectomy (BSCO) and bilateral-epididymal-sparing orchidectomy (BESO). <i>Research Design</i>. Nigerian patients with LAMP were randomised into three surgical arms: BSO, BSCO, and BESO. Expanded Prostate Cancer Index Composite-26 HRQoL and sociodemographic questionnaires were administered before and three months after orchidectomy. Serum testosterone and PSA were measured at 0, 1, 2, and 3 hours; 7 days; and 3 months postoperatively. Pseudotesticular volumes and cosmetic appeal were assessed at 3 months.</p><p><strong>Result: </strong>Sixty-three patients were recruited (24 BSO, 21 BSCO, 18 BESO), 73% of whom were low-income earners. There was no significant difference in the procedure cost nor the PSA or testosterone nadirs achieved over the three-month follow-up period (11.3, 12.6, 15.2 ng/ml (<i>p</i>=0.667) and 0.44, 0.64, 0.79 nmol/l (<i>p</i>=0.603) respectively). Those with pseudotesticles (BSCO, BESO) felt less emasculated (<i>p</i>=0.010). BSCO produced the least sexual bother, highest sexual function, and largest pseudotesticular volumes. The cosmetic appeal scores were similar between groups (77.9 ± 22.8, 81 ± 13.9, and 81.9 ± 22.5, respectively, <i>p</i>=0.858).</p><p><strong>Conclusion: </strong>Endogenous pseudotesticular techniques, when compared with BSO, reduce the negative psychological impact experienced by patients without increasing costs. BSCO produced the best pseudotesticular volumes and postoperative sexual function. This study is registered with the ClinicalTrials.gov of the National Institute of Health U.S. National Library of Medicine as TEPSO study, NCT03744494: Comparison of the Therapeutic Efficacy and Patient Satisfaction of Three Techniques of Bilateral Orchidectomy in Prostate Cancer Patients of a Nigerian Sub-population. Registration completed on 16^th of November, 2018 (registered retrospectively) NCT03744494.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2021 ","pages":"9968570"},"PeriodicalIF":4.2,"publicationDate":"2021-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39948475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of Interleukins 6 and 8 Single Nucleotide Polymorphisms in Prostate Cancer: A Multicenter Study.","authors":"Amany A Ghazy,&nbsp;Mohammed Jayed Alenzi","doi":"10.1155/2021/3825525","DOIUrl":"https://doi.org/10.1155/2021/3825525","url":null,"abstract":"<p><p>The diverse roles of cytokines as IL-6 and IL-8 have been studied in terms of their SNPs in many diseases but their role in prostate cancer (PCa) is still uncertain. <i>Aim</i>. To determine the relevance of IL-6 rs1800795 SNP and/or IL-8 rs2227306 SNP with prostate cancer's risk. <i>Subjects and Methods</i>. 40 PCa patients, 40 benign prostate hyperplasia (BPH) patients, and 40-age-matched-control group were enrolled in the study. Genotyping of IL-6 rs1800795 (G/C) SNP and IL-8 rs2227306 (C/T) SNP was determined using real-time PCR. <i>Results</i>. High frequency of IL-6 rs1800795GG and IL-8 rs2227306CC genotypes was noticed among PCa patients with associated OR 10.091 and 8.143, respectively. Comparisons based on allele frequencies revealed that IL-6G and IL-8C alleles are more frequent among PCa patients than other groups. Presence of IL-6 rs1800795G and IL-8 rs2227306C alleles in the same patient increase PCa risk by 16.7 times. Statistical correlations between PSA ratio and both of IL-6 and IL-8 SNP did not show any significant relation among PCa patients. <i>Conclusion</i>. IL-6 rs1800795G and IL-8 rs2227306C alleles could be considered risk factors for PCa development, particularly if presented together. However, no relation was found between both cytokines SNP and severity of prostate cancer.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2021 ","pages":"3825525"},"PeriodicalIF":4.2,"publicationDate":"2021-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39258625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients.","authors":"Luke L Wang,&nbsp;Brandon L Henslee,&nbsp;Peter B Sam,&nbsp;Chad A LaGrange,&nbsp;Shawna L Boyle","doi":"10.1155/2021/5531511","DOIUrl":"10.1155/2021/5531511","url":null,"abstract":"<p><strong>Objective: </strong>The study investigates the prostate-specific antigen threshold for adding targeted, software-based, magnetic resonance imaging-ultrasound fusion biopsy during a standard 12-core biopsy in biopsy-naïve patients. It secondarily explores whether the targeted biopsy is necessary in setting of abnormal digital rectal examination.</p><p><strong>Methods: </strong>260 patients with suspected localized prostate cancer with no prior biopsy underwent prostate magnetic resonance imaging and were found to have Prostate Imaging Reporting and Data System score ≥ 3 lesion(s). All 260 patients underwent standard 12-core biopsy and targeted biopsy during the same session. Clinically significant cancer was Gleason ≥3 + 4.</p><p><strong>Results: </strong>Percentages of patients with prostate-specific antigen 0-1.99, 2-3.99, 4-4.99, 5-5.99, 6-9.99, and ≥10 were 3.0%, 4.7%, 20.8%, 16.9%, 37.7%, and 16.9%, respectively. Cumulative frequency of clinically significant prostate cancer increased with the addition of targeted biopsy compared with standard biopsy alone across all prostate-specific antigen ranges. The difference in clinically significant cancer detection between targeted plus standard biopsy compared to standard biopsy alone becomes statistically significant at prostate-specific antigen >4.3 (<i>p</i>=0.031). At this threshold, combination biopsy detected 20 clinically significant prostate cancers, while standard detected 14 with 88% sensitivity and 20% specificity. Excluding targeted biopsy in setting of a positive digital rectal exam would save 12.3% magnetic resonance imaging and miss 1.8% clinically significant cancers in our cohort.</p><p><strong>Conclusions: </strong>In biopsy-naïve patients, at prostate-specific antigen >4.3, there is a significant increase in clinically significant prostate cancer detection when targeted biopsy is added to standard biopsy. Obtaining standard biopsy alone in patients with abnormal digital rectal examinations would miss 1.8% clinically significant cancers in our cohort.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2021 ","pages":"5531511"},"PeriodicalIF":4.2,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39220537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}